CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Metformin Lowers Body Weight But Fails to Increase Insulin Sensitivity in Chronic Heart Failure Patients without Diabetes: a Randomized, Double-Blind, Placebo-Controlled Study The Use of Sex-Specific Factors in the Assessment of Women’s Cardiovascular Risk A Combined Optical Coherence Tomography and Intravascular Ultrasound Study on Plaque Rupture, Plaque Erosion, and Calcified Nodule in Patients With ST-Segment Elevation Myocardial Infarction: Incidence, Morphologic Characteristics, and Outcomes After Percutaneous Coronary Intervention Transcatheter versus Surgical Aortic Valve Replacement in Patients with Prior Cardiac Surgery in the Randomized PARTNER 2A Trial Exercise Intolerance in Patients With Heart Failure: JACC State-of-the-Art Review Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women: JACC State-of-the-Art Review Lifestyle Modifications for Preventing and Treating Heart Failure Heart Failure With Recovered Left Ventricular Ejection Fraction: JACC Scientific Expert Panel Impact of Positive and Negative Lesion Site Remodeling on Clinical Outcomes : Insights From PROSPECT Early Surgery or Conservative Care for Asymptomatic Aortic Stenosis

Expert Opinion2017 Feb 28;135(9):819-821.

JOURNAL:Circulation Article Link

Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Left Main and Multivessel Coronary Artery Disease: Do We Have the Evidence?

Gersh BJ, Stone GW, Bhatt DL et al. Keywords: coronary artery bypass grafting; coronary artery disease; stenting

ABSTRACT

Approximately 60 randomized controlled trials performed over the last 3 decades have failed to demonstrate statistically significant differences in death or myocardial infarction (MI) between coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI), apart from a few notable exceptions in which CABG was superior to PCI. The benefits for CABG have been reported in patients with diabetes mellitus with multivessel disease and in patients with and without diabetes mellitus with 3-vessel disease and intermediate or high SYNTAX trial (Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) scores (≥23).